CStone Pharmaceuticals
Quick facts
Phase 3 pipeline
- CS1001+ Fluorouracil+Cisplatin · Oncology
CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects. - CS1001 monoclonal antibody · Oncology
CS1001 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses. - Placebo+ Fluorouracil+Cisplatin · Oncology
This combination uses fluorouracil and cisplatin chemotherapy agents to inhibit DNA synthesis and induce cancer cell death, with placebo as a control arm in the trial design.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: